Doxorubicin hydrochloride

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

No data

Clinical

Clinical Trials

2594 clinical trials

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Lymphoma	D008223	—	C85.9	136	408	184	16	41	706
Breast neoplasms	D001943	EFO_0003869	C50	96	332	129	14	80	595
Sarcoma	D012509	—	—	64	126	50	5	23	242
Large b-cell lymphoma diffuse	D016403	—	C83.3	50	141	54	3	10	228
Ovarian neoplasms	D010051	EFO_0003893	C56	72	102	61	2	16	224
Carcinoma	D002277	—	C80.0	47	104	44	5	34	212
B-cell lymphoma	D016393	—	—	57	122	47	4	8	203
Non-hodgkin lymphoma	D008228	—	C85.9	46	101	47	6	11	187
Leukemia	D007938	—	C95	42	84	49	8	7	173
Ovarian epithelial carcinoma	D000077216	—	—	55	71	43	2	12	163

Show 41 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Neoplasms	D009369	—	C80	95	60	18	—	7	157
Fallopian tube neoplasms	D005185	—	—	31	31	21	—	1	72
Recurrence	D012008	—	—	24	33	13	—	7	67
Neuroblastoma	D009447	EFO_0000621	—	10	22	16	—	3	51
Osteosarcoma	D012516	—	—	10	20	11	—	8	43
Neoplasm metastasis	D009362	EFO_0009708	—	16	22	3	—	4	41
Endometrial neoplasms	D016889	EFO_0004230	—	5	20	18	—	—	41
Peritoneal neoplasms	D010534	—	—	13	19	7	—	6	40
Adenocarcinoma	D000230	—	—	9	19	9	—	2	33
Transitional cell carcinoma	D002295	—	—	8	19	6	—	1	29

Show 128 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Male breast neoplasms	D018567	—	—	5	12	—	—	4	17
Invasive hydatidiform mole	D002820	—	D39.2	2	12	—	—	1	15
Glioblastoma	D005909	EFO_0000515	—	4	8	—	—	—	11
Plasmablastic lymphoma	D000069293	—	C83.3	7	7	—	—	—	11
Large-cell lymphoma immunoblastic	D016400	—	—	7	7	—	—	—	11
Non-small-cell lung carcinoma	D002289	—	—	3	8	—	—	—	10
Aids-related lymphoma	D016483	EFO_1001365	—	3	7	—	—	—	10
Adult t-cell leukemia-lymphoma	D015459	—	C91.5	4	6	—	—	—	9
Urologic neoplasms	D014571	—	C64-C68	4	6	—	—	—	8
Myelodysplastic syndromes	D009190	—	D46	6	4	—	—	—	8

Show 135 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Myelodysplastic-myeloproliferative diseases	D054437	—	—	4	—	—	—	—	4
Appendiceal neoplasms	D001063	EFO_0003880	C18.1	2	—	—	—	2	4
Skin neoplasms	D012878	EFO_0004198	C44	1	—	—	—	1	2
Pleural effusion	D010996	HP_0002202	J90	1	—	—	—	1	2
Pleural neoplasms	D010997	—	—	1	—	—	—	1	2
Castration-resistant prostatic neoplasms	D064129	—	—	1	—	—	—	—	1
Primary myelofibrosis	D055728	—	D47.4	1	—	—	—	—	1
Myelomonocytic leukemia chronic	D015477	—	C93.1	1	—	—	—	—	1
Anemia	D000740	HP_0001903	D64.9	1	—	—	—	—	1
Leukemia myeloid chronic atypical bcr-abl negative	D054438	—	C92.2	1	—	—	—	—	1

Show 21 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Cardiovascular diseases	D002318	HP_0001626	—	—	—	—	—	3	3
Fatigue	D005221	HP_0012378	R53.83	—	—	—	—	2	2
Pseudomyxoma peritonei	D011553	EFO_0007456	—	—	—	—	—	2	2
Thrombosis	D013927	—	—	—	—	—	—	2	2
Carcinoma in situ	D002278	—	D09.9	—	—	—	—	2	2
Taste disorders	D013651	—	—	—	—	—	—	1	1
Dysgeusia	D004408	—	R43.2	—	—	—	—	1	1
Ageusia	D000370	EFO_1001758	—	—	—	—	—	1	1
Hepatitis a	D006506	EFO_0007305	B15	—	—	—	—	1	1
Ataxia	D001259	—	R27.0	—	—	—	—	1	1